Publications by authors named "Yukio Sakata"
Article Synopsis
- Dexamethasone, commonly used to prevent nausea from chemotherapy, has side effects that prompt the search for alternatives without it.
- This study tested the efficacy and safety of palonosetron, aprepitant, and olanzapine in chemotherapy-naïve breast cancer patients, assessing their effectiveness in controlling nausea and vomiting.
- Results showed low total control rates (17.1%) for antiemetic therapies excluding dexamethasone, though olanzapine could be a viable replacement for patients unable to use dexamethasone.
Article Synopsis
- Dexamethasone is commonly used for preventing nausea and vomiting in chemotherapy patients but has notable side effects, leading to the exploration of a steroid-free antiemetic regimen.
- The study evaluated the effectiveness and safety of a combination of palonosetron, aprepitant, and olanzapine in patients receiving cisplatin, finding a total control rate of 31.3% and complete response rates of 61.4%, 84.3%, and 65.1% in different phases.
- While the primary endpoint wasn't met, the complete response rates were comparable to traditional regimens, suggesting this dexamethasone-free option could be beneficial for patients unable to use corticosteroids.
Introduction: In recent years, most molecular target drugs have been administered orally, as prescribed at ambulatory services in hospitals and at patients' homes. Telephone follow-up is increasingly being used in clinical practice for patients needing additional support post-discharge and for the prevention of hospital readmissions. The purpose of this study was to clarify the clinical benefits of telephone follow-up while administering oral anticancer drugs.
View Article and Find Full Text PDFEfficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
JAMA Netw Open
May 2023
Article Synopsis
- The study investigates the effectiveness of olanzapine added to standard antiemetic therapy for patients undergoing cisplatin-based chemotherapy, particularly focusing on those with high risk for chemotherapy-induced nausea and vomiting (CINV).
- This analysis draws from the J-FORCE trial, which included diverse participants aged 20 to 75 across multiple hospitals in Japan, examining various factors like age and history of motion sickness to gauge the drug's added benefits.
- Key outcomes of the trial measure complete response (no vomiting or need for rescue medication) in the delayed phase after chemotherapy, along with several secondary outcomes related to control over CINV based on individual risk factors.
While many studies have demonstrated the prevention of nausea and vomiting in patients receiving moderately or highly emetogenic anti-cancer agents, there are few reports of mildly emetogenic anti-cancer agents. In the present study, we performed a 2-year multi-center study to determine the types and efficacy of antiemetic therapy administered in a total of 77 cancer patients who received mildly emetogenic anti-cancer agents between September 2015 and August 2017. The effectiveness of antiemetic therapy was evaluated based on the frequency of nausea and vomiting and use of rescue medication.
View Article and Find Full Text PDF